Forte Biosciences
Tracked across 5 events · 31 articles · First seen Apr 08, 2026 · Last active Sep 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Forte Biosciences commenced and priced a public offering of its common stock to raise approximately $150 million for working capital and clinical development.
Apr 08, 2026 · 7 articles
Business
Impact: Forte is being acquired at a significant premium; its lead asset FB102 gains access to Argenx's development and commercial capabilities.
Jul 27, 2026 · 6 articles
Tech
Impact: Hosting the symposium and presenting its CY200 candidate and safety switch technologies, Ensysce aims to raise awareness and potentially advance its clinical development. The event is a promotional opportunity but does not alter its financial position.
Aug 20, 2026 · 6 articles
Business
Impact: Ensysce is the developer of PF614-MPAR and announced the enrollment completion, a key milestone for its lead program. The event supports its pipeline progress but does not guarantee approval or commercial success.
Aug 31, 2026 · 6 articles
Business
Impact: Ensysce announced its participation in multiple conferences and events, which may increase visibility among investors and industry stakeholders. No material change in fundamentals.
Sep 02, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Forte Biosciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard